文献速递神经肿瘤

CoREST复合物抑制剂corin在ATRT异种移植模型中抑制肿瘤生长、促进分化并延长生存期

The CoREST complex inhibitor, corin, decreases tumor growth, increases cellular differentiation and extends lifespan in ATRT xenograft models.
PubMed 文献 · Neuro Oncol · 2026-07-21

本研究探讨CoREST抑制复合物在非典型畸胎样横纹肌样瘤(ATRT)中的作用,评估双功能LSD1/HDAC1/2小分子抑制剂corin对ATRT细胞生长、凋亡、分化、基因表达和染色质可及性的影响。结果显示corin抑制各表观遗传亚型ATRT细胞生长,诱导凋亡和分化,增加染色质可及性及神经元分化基因表达,并在原位ATRT小鼠模型中抑制肿瘤生长、显著延长生存期。

要点

  • corin抑制所有表观遗传亚型ATRT细胞生长并诱导凋亡与分化
  • corin在原位ATRT小鼠模型中抑制肿瘤生长并显著延长生存期
  • RCOR2敲低模拟corin效应并使其脱敏,证实corin对CoREST复合物的特异性

核心结论

  • CoREST抑制剂corin在ATRT中抑制肿瘤生长、诱导分化并促进凋亡,显著延长原位ATRT异种移植小鼠的生存期,提示CoREST复合物抑制剂在ATRT患者中具有潜在应用价值。

研究设计与样本

  • 临床前研究:评估双功能LSD1/HDAC1/2小分子CoREST抑制剂corin对ATRT肿瘤细胞生长、凋亡、分化、基因表达和染色质可及性的影响,并在原位ATRT小鼠模型中验证疗效。

主要发现

  • corin抑制ATRT细胞生长,且不受表观遗传亚型影响。
  • corin增加肿瘤细胞凋亡和分化。
  • ATAC-seq显示corin处理后的ATRT细胞染色质可及性增加,变化见于与神经元分化和突触功能相关的基因。
  • RNA-seq证实corin处理的ATRT细胞中神经元分化基因表达增加。
  • RCOR2敲低模拟corin效应并使细胞对药物脱敏,证实corin对CoREST复合物的特异性。

临床怎么用

  • corin在ATRT临床前模型中显示抗肿瘤活性和生存获益,支持进一步临床转化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atypical teratoid rhabdoid tumor (ATRT) is the most common malignant brain tumor in infants. ATRT is associated with inactivation/deletion of SMARCB1, a member of the SWI/SNF chromatin remodeling complex. SMARCB1 loss contributes to tumorigenicity by compromising SWI/SNF activity at specific loci associated with the CoREST repressor complex, which regulates transcription at critical gene promoters and enhancers. We therefore explored the role of the CoREST repressor complex in ATRT. METHODS: We evaluated the effects of the bifunctional LSD1/HDAC1/2 small molecule CoREST inhibitor, corin, on ATRT tumor cell growth, apoptosis, differentiation, gene expression and chromatin accessibility. RESULTS: Corin inhibited the growth of ATRT cells regardless of their epigenetic subgroup. Corin caused increased tumor cell apoptosis and differentiation. ATAC-seq showed increased chromatin accessibility in corin-treated ATRT cells, with changes seen at genes associated with neuronal differentiation and synaptic function. RNA-seq confirmed increased expression of neuronal differentiation genes in ATRT cells treated with corin. Knockdown of RCOR2 phenocopied the effects of corin, and desensitized the cells to the drug, confirming corin specificity to the CoREST complex. Corin suppressed orthotopic ATRT tumor growth, leading to significant extension of lifespan in ATRT mouse models. Corin caused increased histone acetylation (H3K9ac) and methylation (H3K4Me1) in ATRT orthotopic xenografts, consistent with on-target pharmacodynamics. CONCLUSIONS: The CoREST inhibitor, corin, suppressed tumor growth, induced differentiation, and promoted apoptosis in ATRT leading to significantly increased survival of mice bearing ATRT orthotopic xenografts. Our results suggest a potential application of CoREST complex inhibitors in patients with ATRT. Atypical teratoid rhabdoid tumor (ATRT) is the most common malignant brain tumor of babies. The DNA change that is found in most ATRT tumors prevents the tumor cells from maturing into neurons, the thinking cells of the brain. A new drug, called corin, unblocks maturation programs. Corin forces tumor cells out of their immature state and causes them to stop growing. Corin treatment of mice that had human ATRT tumors implanted into their brains led to maturation of tumor cells and longer survival of mice. These results tell us that corin could be a useful treatment for children with ATRT.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Geethadevi A, Vaidya N, Fisher RJ, et al. The CoREST complex inhibitor, corin, decreases tumor growth, increases cellular differentiation and extends lifespan in ATRT xenograft models. Neuro Oncol. 2026. PMID: 42479134. doi:10.1093/neuonc/noag160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。